Beam Therapeutics Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Beam Therapeutics Inc. (BEAM) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$217.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-04
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$122.68M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$94.32M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $244.30M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$113.82M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$79.99M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$376.74M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$132.53M.
- Beam Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$289.09M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$122.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$217.00M 10-Q · filed 2026-08-04 | $27.30M derived: sum of 3 quarters · filed 2026-08-04 | -$86.52M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | -$94.32M 10-Q · filed 2026-05-07 | $149.98M derived: sum of 2 quarters · filed 2026-05-07 | $36.16M derived: sum of 3 quarters · filed 2026-05-07 | -$65.98M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $244.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $130.48M derived: sum of 2 quarters · filed 2026-02-24 | $28.34M derived: sum of 3 quarters · filed 2026-08-04 | -$79.99M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | -$113.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$215.96M derived: sum of 2 quarters · filed 2026-08-04 | -$324.29M 10-Q · filed 2025-11-04 | -$414.64M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | -$102.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$210.47M 10-Q · filed 2026-08-04 | -$211.56M 10-Q · filed 2025-08-05 | -$300.82M derived: sum of 3 quarters · filed 2026-08-04 | -$397.49M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$108.33M 10-Q · filed 2026-05-07 | -$109.27M 10-Q · filed 2025-05-06 | -$198.68M derived: sum of 2 quarters · filed 2026-05-07 | -$295.35M derived: sum of 3 quarters · filed 2026-05-07 | -$386.40M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$90.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$187.02M derived: sum of 2 quarters · filed 2026-02-24 | -$278.07M derived: sum of 3 quarters · filed 2026-02-24 | -$376.74M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$96.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$187.72M derived: sum of 2 quarters · filed 2025-11-04 | -$286.39M 10-Q · filed 2025-11-04 | -$143.59M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | -$91.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$189.72M 10-Q · filed 2025-08-05 | -$46.92M derived: sum of 3 quarters · filed 2026-02-24 | -$143.01M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | -$98.67M 10-Q · filed 2025-05-06 | $44.13M derived: sum of 2 quarters · filed 2026-02-24 | -$51.96M derived: sum of 3 quarters · filed 2026-02-24 | -$134.74M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $142.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $46.71M derived: sum of 2 quarters · filed 2026-02-24 | -$36.07M derived: sum of 3 quarters · filed 2026-02-24 | -$132.53M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | -$96.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$178.86M derived: sum of 2 quarters · filed 2024-11-05 | -$275.32M 10-Q · filed 2024-11-05 | -$313.67M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-06-30 | -$82.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$179.24M 10-Q · filed 2024-08-06 | -$217.59M derived: sum of 3 quarters · filed 2025-02-25 | -$327.16M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-03-31 | -$96.46M 10-Q · filed 2024-05-07 | -$134.81M derived: sum of 2 quarters · filed 2025-02-25 | -$244.38M derived: sum of 3 quarters · filed 2025-02-25 | -$316.33M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | -$38.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$147.92M derived: sum of 2 quarters · filed 2025-02-25 | -$219.87M derived: sum of 3 quarters · filed 2025-02-25 | -$289.09M 10-K · filed 2025-02-25 | ||
| 2022-09-30 | -$109.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$181.53M derived: sum of 2 quarters · filed 2023-11-08 | -$250.74M 10-Q · filed 2023-11-08 | -$315.45M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | -$71.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$141.16M 10-Q · filed 2023-08-08 | -$205.87M derived: sum of 3 quarters · filed 2024-02-27 | -$233.99M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$69.21M 10-Q · filed 2023-05-10 | -$133.92M derived: sum of 2 quarters · filed 2024-02-27 | -$162.04M derived: sum of 3 quarters · filed 2024-02-27 | -$238.29M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | -$64.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$92.83M derived: sum of 2 quarters · filed 2024-02-27 | -$169.08M derived: sum of 3 quarters · filed 2024-02-27 | -$370.64M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | -$28.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$104.37M derived: sum of 2 quarters · filed 2022-11-07 | -$305.93M 10-Q · filed 2022-11-07 | -$401.39M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$76.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$277.81M 10-Q · filed 2022-08-09 | -$373.28M derived: sum of 3 quarters · filed 2023-02-28 | -$407.73M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$201.56M 10-Q · filed 2022-05-09 | -$297.02M derived: sum of 2 quarters · filed 2023-02-28 | -$331.48M derived: sum of 3 quarters · filed 2023-02-28 | -$365.69M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$95.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$129.92M derived: sum of 2 quarters · filed 2023-02-28 | -$164.13M derived: sum of 3 quarters · filed 2023-02-28 | -$194.59M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$34.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$68.67M derived: sum of 2 quarters · filed 2021-11-08 | -$99.13M 10-Q · filed 2021-11-08 | -$126.98M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | -$34.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$64.68M 10-Q · filed 2021-08-10 | -$92.53M derived: sum of 3 quarters · filed 2022-02-28 | -$111.53M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$30.46M 10-Q · filed 2021-05-11 | -$58.31M derived: sum of 2 quarters · filed 2022-02-28 | -$77.31M derived: sum of 3 quarters · filed 2022-02-28 | -$95.17M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$27.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$46.85M derived: sum of 2 quarters · filed 2022-02-28 | -$64.72M derived: sum of 3 quarters · filed 2022-02-28 | -$78.33M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$36.87M derived: sum of 2 quarters · filed 2020-11-10 | -$50.48M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | -$17.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$31.47M 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | -$13.61M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |